Abstract
The Wilms' tumor geneWT1 was first identified as the gene responsible for a childhood renal tumor, Wilms' tumor. This gene encodes for a zinc finger-containing transcription factor. Although originally identified as a tumor suppressor gene,WT1 is overexpressed in a variety of hematologic malignancies and solid tumors. Recently, WT1 protein has been considered as a new molecular target of cancer immunotherapy for several solid tumors. In the present study, we investigated the expression of WT1 protein andWT1 mRNA in glioblastomas and medulloblastomas. Forty-eight of 51 glioblastoma samples (94%) showed immunohistochemically positive staining of WT1 protein, whereas all 10 medulloblastomas examined were negative. According to the immunohistochemical expression of WT1 protein,WT1 mRNA was also highly expressed in the same glioblastoma tissue. Our results suggest that theWT1 gene may play an important role in the tumorigenesis of glioblastoma, in contrast to medulloblastoma, and be integral in the development of the immunotherapy targeting WT1 protein in patients with glioblastoma.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Call KM, Glaser T, Ito CY, et al (1990) Isolation and characterization of a zinc finger polypeptide gene at the human chromosome 11 Wilms' tumor locus. Cell 60:509–520
Gessler M, Poustka A, Cavenee W, et al (1990) Homozygous deletion in Wilms' tumours of a zinc-finger gene identified by chromosome jumping. Nature 343:774–778
Haber DA, Englert C, Maheswaran S (1996) Functional properties of WT1. Med Pediatr Oncol 27:453–455
Hewitt SM, Hamada S, McDonnell TJ, et al (1995) Regulation of the proto-oncogenes bcl-2 and c-myc by the Wilms' tumor suppressor gene WT1. Cancer Res 55:5386–5389
Menke AL, Schedl A (2003) WT1 and glomerular function. Semin Cell Dev Biol 14:233–240
Inoue K, Ogawa H, Sonoda Y, et al (1997) Aberrant overexpression of the Wilms tumor gene (WT1) in human leukemia. Blood 89:1405–1412
Silberstein GB, Van Horn K, Strickland P, et al (1997) Altered expression of the WT1 Wilms tumor suppressor gene in human breast cancer. Proc Natl Acad Sci U S A 94:8132–8137
Park S, Schalling M, Bernard A, et al (1993) The Wilms tumour gene WT1 is expressed in murine mesoderm-derived tissues and mutated in a human mesothelioma. Nat Genet 4:415–420
Campbell CE, Kuriyan NP, Rackley RR, et al (1998) Constitutive expression of the Wilms tumor suppressor gene (WT1) in renal cell carcinoma. Int J Cancer 78:182–188
Yamagami T, Sugiyama H, Inoue K, et al (1996) Growth inhibition of human leukemic cells by WT1 (Wilms tumor gene) antisense oligodeoxynucleotides: implications for the involvement of WT1 in leukemogenesis. Blood 87:2878–2884
Sugiyama H (2002) Cancer immunotherapy targeting WT1 protein. Int J Hematol 76:127–132
Kleihues P, Cavenee WK (2000) Pathology and genetics of tumours of the nervous system. IARC, Lyon
Haber DA, Sohn RL, Buckler AJ, et al (1991) Alternative splicing and genomic structure of the Wilms tumor gene WT1. Proc Natl Acad Sci U S A 88:9618–9622
Oji Y, Ogawa H, Tamaki H, et al (1999) Expression of the Wilms' tumor gene WT1 in solid tumors and its involvement in tumor cell growth. Jpn J Cancer Res 90:194–204
Loeb DM, Sukumar S (2002) The role of WT1 in oncogenesis: tumor suppressor or oncogene? Int J Hematol 76:117–126
Loeb DM, Korz D, Katsnelson M, et al (2002) Cyclin E is a target of WT1 transcriptional repression. J Biol Chem 277:19627–19632
Liu XW, Gong LJ, Guo LY, et al (2001) The Wilms' tumor gene product WT1 mediates the down-regulation of the rat epidermal growth factor receptor by nerve growth factor in PC12 cells. J Biol Chem 276:5068–5073
Ellisen L (2002) Regulation of gene expression by WT1 in development and tumorigenesis. Int J Hematol 76:110–116
Oji Y, Yamamoto H, Nomura M, et al (2003) Overexpression of the Wilms' tumor gene WT1 in colorectal adenocarcinoma. Cancer Sci 94:712–717
Niksic M, Slight J, Sanford JR et al (2004) The Wilms' tumour protein (WT1) shuttles between nucleus and cytoplasm and is present in functional polysomes. Hum Mol Genet 13:463–471
Gaiger A, Reese V, Disis ML, et al (2000) Immunity to WT1 in the animal model and in patients with acute myeloid leukemia. Blood 96:1480–1489
Oka Y, Udaka K, Tsuboi A, et al (2000) Cancer immunotherapy targeting Wilms' tumor gene WT1 product. J Immunol 164:1873–1880
Elisseeva OA, Oka Y, Tsuboi A, et al (2002) Humoral immune responses against Wilms tumor gene WT1 product in patients with hematopoietic malignancies. Blood 99:3272–3279
Ohminami H, Yasukawa M, Fujita S (2000) HLA class I-restricted lysis of leukemia cells by a CD8(+) cytotoxic T-lymphocyte clone specific for WT1 peptide. Blood 95:286–293
Tsuboi A, Oka Y, Osaki T, et al (2004) WT1 peptide-based immunotherapy for patients with lung cancer: report of two cases. Microbiol Immunol 48:175–184
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Nakahara, Y., Okamoto, H., Mineta, T. et al. Expression of the Wilms' tumor gene product WT1 in glioblastomas and medulloblastomas. Brain Tumor Pathol 21, 113–116 (2004). https://doi.org/10.1007/BF02482185
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/BF02482185